Otonomy Reports Positive Top-Line Results from Phase 1/2 Clinical Trial of OTO-313 in Patients with Tinnitus

Back to Jobs

OTO -313 demonstrated a higher proportion of responders than placebo Given clear signal in this proof of concept study, Otonomy plans to advance OTO -313 to full Phase 2 development in tinnitus OTO -313 was well-tolerated with lower incidence of adverse events than placebo group Management will

Apply Now